The FDA’s final guidance on manufacturer communications with payors, issued June 12, provides additional recommendations for approved or cleared medical devices and unapproved products and unapproved uses of approved/cleared products rather than only investigational products. In announcing the final guidance, the agency noted nearly three-quarters of the comments (17 of 23) t... Read More